Pfizer (NY:PFE)

25.15 -0.12 (-0.47%)

Official Closing Price Updated: 4:10 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Most active S&P500 stocks in Tuesday's session ↗

Today 14:05 EST

Via Chartmill

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

Today 12:56 EST

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Via MarketMinute

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

Today 10:40 EST

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Via PredictStreet

Topics Economy Intellectual Property

The Evolution of a Giant: A Deep Dive into the ‘New’ Johnson & Johnson (JNJ) in 2026

Today 10:19 EST

As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New...

Via PredictStreet

Topics Artificial Intelligence Bankruptcy Economy

3 Value Stocks That Fall Short

January 12, 2026

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Why Tempus AI Stock Rose Today ↗

January 12, 2026

The data provider's artificial intelligence-driven solutions are accelerating drug discovery.

Via The Motley Fool

Topics Artificial Intelligence

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...

Via MarketMinute

Topics Economy Intellectual Property World Trade

Pfizer CEO Eyes Big Push Towards Obesity Drug Development In 2026 After $10B Metsera Acquisition ↗

January 12, 2026

Pfizer’s CEO Albert Bourla is looking to initiate about 10 late-stage trials of the company’s new obesity drugs.

Via Stocktwits

Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗

January 12, 2026

Via Chartmill

Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial ↗

January 12, 2026

Pfizer shared new trial data showing its cancer drug combo helped shrink tumors more often than standard treatment in advanced colorectal cancer patients at a major oncology meeting.

Via Benzinga

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗

January 11, 2026

It has strong momentum thanks to its current portfolio and several catalysts on the horizon.

Via The Motley Fool

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

January 10, 2026

From Pfizer Inc.

Via Business Wire

Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On

January 09, 2026

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading...

Via Barchart.com

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

Via MarketMinute

The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance

January 09, 2026

As the first full week of 2026 unfolds, the pharmaceutical landscape is witnessing a seismic shift led by the Danish healthcare giant Novo Nordisk (NYSE: NVO). On January 5, 2026, the company...

Via MarketMinute

Topics Economy

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic...

Via PredictStreet

Topics Earnings Economy Intellectual Property

BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism

January 09, 2026

In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The...

Via MarketMinute

Topics Intellectual Property

Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026 ↗

January 09, 2026

It could be another tough year for the once-soaring drugmaker.

Via The Motley Fool

Topics Intellectual Property

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...

Via PredictStreet

Topics Initial Public Offering Intellectual Property

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

American Trade Resilience: Deficit Hits 17-Year Low as Export Surge and Tariff Shocks Reshape Global Commerce

January 08, 2026

In a landmark shift for the American economy, the U.S. trade deficit has plummeted to its lowest level in 17 years, signaling a profound transformation in global supply chains and domestic production....

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Trade War 2.0: Markets Braced as Trump’s 2026 Tariff ‘Salvos’ Reshape the Global Supply Chain

January 08, 2026

As of January 8, 2026, the global financial landscape is undergoing a seismic shift driven by President Trump’s latest round of "tariff salvos." These aggressive trade policies, which dominated the...

Via MarketMinute

Topics Economy Government World Trade

U.S. Trade Deficit Plummets to 2009 Levels as 'Liberation Day' Tariffs and Gold Surge Reshape Global Trade

January 08, 2026

On January 8, 2026, the U.S. Bureau of Economic Analysis and the Census Bureau released a landmark report revealing that the nation’s trade deficit has narrowed to its lowest level since the height of...

Via MarketMinute

Topics Economy Supply Chain World Trade

Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks ↗

January 08, 2026

These high-yielding dividend stocks pay 5% or more, and make for safe income investments to hold on to.

Via The Motley Fool

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026? ↗

January 08, 2026

This big pharma stock still faces significant challenges in the new year.

Via The Motley Fool

Topics Government World Trade

1 Stock Under $50 Worth Your Attention and 2 That Underwhelm

January 07, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

Via MarketMinute

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.